Quince Therapeutics公布共济失调-毛细血管扩张症Edsp关键三期NEAT临床试验主要结果

美股速递
Jan 30

Quince Therapeutics, Inc. 近日披露了其针对共济失调-毛细血管扩张症(Ataxia-Telangiectasia)研发药物Edsp的关键性三期NEAT临床试验的初步结果。此次公布的数据标志着该疗法在临床开发进程中的重要节点,为后续评估提供了关键依据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10